angioedema; urticaria; allergic reaction; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra-web. regulatory number: nl-lrb-00779189. a 36 year-old female patient received bnt162b2 (comirnaty), administration date 02may2021 (lot number: unknown) at the age of 36 years as dose 1, 0.3 ml single for covid-19 immunisation. the patient's relevant medical history was not reported. patient had no previous covid-19 infection. concomitant medication(s) included: levothyroxine. the following information was reported: angioedema (medically significant) with onset 09may2021, outcome "not recovered", described as "angioedema"; urticaria (non-serious) with onset 09may2021, outcome "not recovered", described as "urticaria"; hypersensitivity (non-serious) with onset 09may2021, outcome "not recovered", described as "allergic reaction". the patient underwent the following laboratory tests and procedures: investigation: unknown result, notes: to exclude rheumatism; x-ray: unknown result, notes: to exclude a rheumatic etiology. therapeutic measures were taken as a result of angioedema, urticaria, hypersensitivity. the patient was treated with antihistamine. patient received dose 2 0.3 ml single on 06jun2021, and dose 3 pfizer on 01sep2022. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: photos of the hands and feet; result unstructured data: test result:unknown result; comments: to exclude rheumatism; test name: x- rays; result unstructured data: test result:unknown result; comments: to exclude a rheumatic etiology

na

na